CN1836720A - Chinese medicine composition for treating arthritis or gout and preparing method thereof - Google Patents
Chinese medicine composition for treating arthritis or gout and preparing method thereof Download PDFInfo
- Publication number
- CN1836720A CN1836720A CNA2005100119613A CN200510011961A CN1836720A CN 1836720 A CN1836720 A CN 1836720A CN A2005100119613 A CNA2005100119613 A CN A2005100119613A CN 200510011961 A CN200510011961 A CN 200510011961A CN 1836720 A CN1836720 A CN 1836720A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- granule
- present
- radix
- medicine composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The present invention discloses one kind of Chinese medicine composition and its preparation process. The Chinese medicine composition contains the effective components of atractylodes rhizome, coix seed, earthworm, tetramdra root, phellodendron bark and other seven kinds of Chinese medicinal materials. It may be prepared into granule, tablet, capsule or other common Chinese preparation form. It has the functions of dispelling wind, eliminating dampness, clearing away heat, relieving swelling, dredging meridian and relieving pain, and may be used in treating rheumatic arthritis, rheumatoid arthritis and gout.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, is a kind of Chinese medicine composition for the treatment of rheumatic arthritis or rheumatoid arthritis or gout specifically, the invention still further relates to the preparation method of this Chinese medicine composition.
Background technology
Rheumatism has the branch of broad sense and narrow sense.Generalized rheumatism general reference influences osteoarthrosis and surrounding soft tissue thereof, as gang's disease of tendon, synovial bursa, fascia etc.The rheumatism of narrow sense is a kind of diseases associated with inflammation of the acute or chronic general connective tissue of outbreak repeatedly that causes by after the upper respiratory tract infection due to the A group Hemolytic streptococcus, and is the most serious with heart and joint involvement.The rheumatism sorted generalization can be divided into 10 big classes, kind of rheumatism surplus in the of 100, and as rheumatic arthritis, rheumatoid arthritis, gout etc. all belong to this disease.Because most of rheumatismal causes of disease and pathogenesis are also not clear, doctor trained in Western medicine is used medicines such as glucocorticoids, immunosuppressant, can only suit the medicine to the illness, and cure the symptoms, not the disease, and toxic and side effects is very big, can not life-time service.Motherland's medical science is thought, diseases such as rheumatic arthritis, rheumatoid arthritis, gout all belong to traditional Chinese medical science arthromyodynia category, promptly because exopathogen invasion and attack human bodies such as wind, cold, wet, heat, the impatency meridians, due to QI-blood circulation is smooth with muscle, muscles and bones, joint ache, numbness, weighing, joint stuffiness, even the disease that the scorching hot grade of arthroncus is a main clinical manifestation.Rheumatic arthritis, rheumatoid arthritis, gout etc. belong to the damp and hot resistance network disease in the arthromyodynia, how belong to because of body constitution is plain preponderance of YANG QI, in intrinsic heat is arranged, experience wind, cold, wet, hot heresy, or anemofrigid-damp arthralgia is prolonged does not heal, heresy is stayed meridians, accumulates to turn to due to the heat.
In view of rheumatismal medicine of the treatment that does not have better curative effect at present and method, thus a kind of good effect of demand still, taking convenience, the Chinese medicine for oral administration that side effect is little.This Chinese medicine composition proves the effect with treatment rheumatic arthritis or rheumatoid arthritis or gout through animal experiment and clinical verification for many years.
Summary of the invention
Purpose of the present invention just provides a kind of Chinese medicine composition for the treatment of rheumatic arthritis or rheumatoid arthritis or gout.
Another object of the present invention just provides the preparation method of this Chinese medicine composition.
The traditional Chinese medical science thinks that rheumatic arthritis, rheumatoid arthritis, gout etc. belong to the damp and hot resistance network disease in the arthromyodynia, how belong to because of body constitution is plain preponderance of YANG QI, in intrinsic heat is arranged, experience wind, cold, wet, hot heresy, or anemofrigid-damp arthralgia is prolonged does not heal, heresy is stayed meridians, accumulates to turn to due to the heat.Therefore determine that the rule of treatment is an expelling wind and removing dampness, clearing heat for detumescence, dredging collateral to stop pain.The effective ingredient of the present composition is exactly under the guidance of this treatment rule, selects for use following Chinese crude drug combined preparation to form.
The preparation raw material of Chinese medicine composition effective ingredient of the present invention and weight ratio thereof are Rhizoma Atractylodis 5-15 part, raw pearl barley 10-30 part, Pheretima 5-15 part, Radix Stephaniae Tetrandrae 7-22 part, Cortex Phellodendri 5-15 part, Rhizoma Dioscoreae Hypoglaucae 7-22 part, Caulis Lonicerae 10-30 part, Radix Saposhnikoviae 5-15 part, Fructus Forsythiae 7-22 part, Radix Clematidis 6-18 part, Radix Cyathulae 7-22 part, Ramulus Mori 10-30 part.
The preparation raw material weight ratio of preferred Chinese medicine composition effective ingredient of the present invention is: Rhizoma Atractylodis 7-13 part, raw pearl barley 15-25 part, Pheretima 7-13 part, Radix Stephaniae Tetrandrae 10-18 part, Cortex Phellodendri 7-13 part, Rhizoma Dioscoreae Hypoglaucae 10-18 part, Caulis Lonicerae 15-25 part, Radix Saposhnikoviae 7-13 part, Fructus Forsythiae 10-18 part, Radix Clematidis 9-15 part, Radix Cyathulae 10-18 part, Ramulus Mori 15-25 part.
The preparation of the effective ingredient of Chinese medicine composition of the present invention can be that the coarse powder with above-mentioned raw material of Chinese medicine minces or prepared slices of Chinese crude drugs decocting together, filters, and obtains the water extract of above-mentioned raw materials; Or make the alcohol extract of above-mentioned raw materials with decoction and alcohol sedimentation technique.
The effective ingredient of Chinese medicine composition of the present invention is preferably as follows preparation: Rhizoma Atractylodis, Fructus Forsythiae, Radix Saposhnikoviae are extracted volatile oil; All the other 9 flavor decoctings boil 2-3 time; Merge whole extracting solution, filter, be evaporated to relative density and be about 1.10 fluid extract, add 2-3 by weight and doubly measure ethanol and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.1-1.4 (50 ℃), promptly.
Chinese medicine composition of the present invention can be made various common formulations together with its effective ingredient and/or acceptable accessories, as tablet, capsule or granule etc.
Acceptable accessories of the present invention includes but not limited to: starch, dextrin, Icing Sugar, low-substituted hydroxypropyl cellulose, carboxymethyl starch sodium, lactose, magnesium stearate, differential silica gel, Pulvis Talci.
Chinese medicine composition of the present invention has expelling wind and removing dampness, clearing heat for detumescence, and the dredging collateral to stop pain effect can be used for treating rheumatic Bi syndrome, particularly rheumatic arthritis or rheumatoid arthritis or gout.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.
Embodiment 1: the preparation of tablet of the present invention
Take by weighing following raw materials in weight: Rhizoma Atractylodis 10g, raw pearl barley 20g, Pheretima 10g, Radix Stephaniae Tetrandrae 15g, Cortex Phellodendri 10g, Rhizoma Dioscoreae Hypoglaucae 15g, Caulis Lonicerae 20g, Radix Saposhnikoviae 10g, Fructus Forsythiae 15g, Radix Clematidis 12g, Radix Cyathulae 15g, Ramulus Mori 20g.
Fructus Forsythiae, Semen Coicis, Radix Stephaniae Tetrandrae are pulverized, cross 100 mesh sieves, all the other 9 flavor medicines water together decoct twice, merge, filter, filtrate is concentrated into the clear paste of relative density 1.1 (50 ℃), with clear paste and above-mentioned medicinal powder and appropriate amount of starch, makes granule, dry, add magnesium stearate 0.3%, tabletting promptly gets tablet of the present invention.
Embodiment 2: the preparation of granule of the present invention
Take by weighing following raw materials in weight: Rhizoma Atractylodis 15g, raw pearl barley 30g, Pheretima 15g, Radix Stephaniae Tetrandrae 15g, Cortex Phellodendri 15g, Rhizoma Dioscoreae Hypoglaucae 20g, Caulis Lonicerae 30g, Radix Saposhnikoviae 15g, Fructus Forsythiae 20g, Radix Clematidis 15g, Radix Cyathulae 15g, Ramulus Mori 30g.
Rhizoma Atractylodis, Fructus Forsythiae, Radix Saposhnikoviae are extracted volatile oil; All the other 9 flavor decoctings boil secondary; Merge whole extracting solution, filter, be evaporated to relative density and be 1.15 fluid extract, add 3 times of amount ethanol (more than 90%) by weight and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.4 (50 ℃), qinghuo reagent 1g, lactose 2.4g, dextrin 1g granulates, dry, cross the 10-60 mesh sieve, add the volatile oil mixing, promptly get granule of the present invention.
Embodiment 3: the preparation of capsule of the present invention
Take by weighing following raw materials in weight: Rhizoma Atractylodis 5g, raw pearl barley 10g, Pheretima 5g, Radix Stephaniae Tetrandrae 7g, Cortex Phellodendri 5g, Rhizoma Dioscoreae Hypoglaucae 7g, Caulis Lonicerae 10g, Radix Saposhnikoviae 5g, Fructus Forsythiae 7g, Radix Clematidis 6g, Radix Cyathulae 7g, Ramulus Mori 10g.
Rhizoma Atractylodis, raw pearl barley, Pheretima, Radix Stephaniae Tetrandrae, Cortex Phellodendri, Rhizoma Dioscoreae Hypoglaucae , Caulis Lonicerae, Radix Saposhnikoviae, Fructus Forsythiae, Radix Clematidis, Radix Cyathulae, Ramulus Mori water are decocted twice, merge, filter, filtrate is concentrated into the clear paste of relative density 1.4 (50 ℃), make granule with dextrin, starch, drying, encapsulated, promptly get capsule of the present invention.
Embodiment 4: the preparation of tablet of the present invention
Take by weighing following raw materials in weight: Rhizoma Atractylodis 161.7g, raw pearl barley 323.4g, Pheretima 161.7g, Radix Stephaniae Tetrandrae 242.7g, Cortex Phellodendri 161.7g, Rhizoma Dioscoreae Hypoglaucae 242.7g, Caulis Lonicerae 323.4g, Radix Saposhnikoviae 161.7g, Fructus Forsythiae 242.7g, Radix Clematidis 194.1g, Radix Cyathulae 242.7g, Ramulus Mori 323.4g.
Fructus Forsythiae, Semen Coicis, Radix Stephaniae Tetrandrae are pulverized, cross 100 mesh sieves, all the other 9 flavor medicines water together decoct twice, merge, and filter, filtrate is concentrated into the clear paste of relative density 1.4 (50 ℃), with clear paste and above-mentioned medicinal powder mixing, add appropriate amount of starch, make particle drying, add magnesium stearate 0.3%, tabletting promptly gets tablet of the present invention.
Embodiment 5: the preparation of granule of the present invention
Take by weighing following raw materials in weight: Rhizoma Atractylodis 15g, raw pearl barley 30g, Pheretima 15g, Radix Stephaniae Tetrandrae 22g, Cortex Phellodendri 15g, Rhizoma Dioscoreae Hypoglaucae 22g, Caulis Lonicerae 30g, Radix Saposhnikoviae 15g, Fructus Forsythiae 22g, Radix Clematidis 18g, Radix Cyathulae 22g, Ramulus Mori 30g.
Rhizoma Atractylodis, Fructus Forsythiae, Radix Saposhnikoviae are extracted volatile oil; All the other 9 flavor decoctings boil secondary; Merge whole extracting solution, filter, be evaporated to relative density and be 1.15 fluid extract, add 2 times of amount ethanol by weight and stir evenly, leave standstill, get supernatant, reclaim ethanol, be concentrated into the clear paste of relative density 1.1 (50 ℃), qinghuo reagent 1g, Icing Sugar 2.4g, dextrin 1g granulates, dry, cross the 10-60 mesh sieve, add the volatile oil mixing, promptly get granule of the present invention.
Embodiment 6: capsule of the present invention
According to embodiment 3 described methods, difference is to select following raw materials in weight for use: Rhizoma Atractylodis 7g, raw pearl barley 25g, Pheretima 7g, Radix Stephaniae Tetrandrae 18g, Cortex Phellodendri 13g, Rhizoma Dioscoreae Hypoglaucae 10g, Caulis Lonicerae 15g, Radix Saposhnikoviae 13g, Fructus Forsythiae 10g, Radix Clematidis 9g, Radix Cyathulae 18g, Ramulus Mori 15g.
Embodiment 7: tablet of the present invention
According to embodiment 1 described method, difference is to select following raw materials in weight for use: Rhizoma Atractylodis 13g, raw pearl barley 15g, Pheretima 13g, Radix Stephaniae Tetrandrae 10g, Cortex Phellodendri 7g, Rhizoma Dioscoreae Hypoglaucae 18g, Caulis Lonicerae 25g, Radix Saposhnikoviae 7g, Fructus Forsythiae 18g, Radix Clematidis 15g, Radix Cyathulae 10g, Ramulus Mori 25g.
Embodiment 8: granule of the present invention
According to embodiment 2 described methods, difference is to select following raw materials in weight for use: Rhizoma Atractylodis 43.9g, raw pearl barley 87.8g, Pheretima 43.9g, Radix Stephaniae Tetrandrae 65.8g, Cortex Phellodendri 43.9g, Rhizoma Dioscoreae Hypoglaucae 65.8g, Caulis Lonicerae 87.8g, Radix Saposhnikoviae 43.9g, Fructus Forsythiae 65.8g, Radix Clematidis 52.6g, Radix Cyathulae 65.8g, Ramulus Mori 87.8g.
Below set forth the effect of this Chinese medicine composition by test.
Animal:
Ages in Wistar rat 8 week, body weight 190-210g, in age in Kunming mouse 6-7 week, body weight 18-22g is provided by animal housing of Shenyang Pharmaceutical University, the animal random packet is placed on temperature 24-25 ℃, relative humidity 50-70%, in the sound damping animal housing, fluorescent lamp lighting, 08:00-20:00h is an illumination period, all the other time dark.10 one cage group supports of animal per are freely ingested, are drunk water.Adapt to above-mentioned environment and be used for experiment after one week.
Be subjected to test product and reagent:
Tried thing granule of the present invention lot number is provided by Benxi Tianyin Pharmaceutical Co., Ltd: 050201, granule of the present invention is a yellow particle, faces the time spent to be made into outstanding agent for examination with distilled water.Uric acid sodium: U.S. Sigma company, lot number: 076H5013.Hydrocortisone: Shenyang No. 1 Pharmaceutical Factory, lot number: 950605, ZHENGQINGFENGTONGNING PIAN: lot number is provided by Baiyunshan Qingzheng Pharmaceutical Co., Ltd: 9903132, glacial acetic acid: Dongxing, Shenyang City chemical reagent work, lot number 011110.Dinitrochlorobenzene, Shenyang reagent one factory, lot number: 041110.Indomethacin: Linfen, Shanxi Province biochemical-pharmaceutical factory, lot number: 020411302.Sodium sulfide: Tianjin reagent six factories, lot number: 920306.Bacillus calmette-guerin vaccine: Changchun institute of Biological Products, lot number: 050401.Lanoline: Beijing extensive and profound in meaning star biotechnology responsibility company limited, lot number: 000512.Liquid paraffin: Dongxing, Shenyang City chemical reagent work, lot number: 020805.
Instrument:
The small-sized volume measuring instrument of MTC-9802: produce by Shenyang Pharmaceutical University.JN-B type precision torsion balance: Shanghai Second Balance Factory, DT-100 balance: Beijing Optical Instrument Factory.JB-2 type constant temperature blender with magnetic force: Shanghai thunder magnetic instrument plant.
Experimental technique:
1, granule of the present invention is to the influence of rat assist agent arthritis
60 of rats, ♀ ♂ half and half divides 6 groups at random by body weight. and first group of 10 rat is the normal control group, in its right back sufficient sole of the foot intradermal injection normal saline 0.1ml/ only; The complete freund adjuvant 0.1ml/ of the right back sufficient sole of the foot intradermal injection of all the other rats only, before the adjuvant injection and the 3h of injection back, 18h measured respectively and respectively to organize sufficient volume below the right ankle of the rat joint in 3,6,9,12,15,18,21 days.And cause the secondary reactions of the 10th day opening entry animal in scorching back in adjuvant, do the sxemiquantitative record with 5 grades of point systems
(2)(0 minute: do not have red and swollen; 1 minute: little toe joint was swollen slightly; 2 minutes: toe joint and pedal swelling; 3 minutes: the following foot swelling of ankle joint; 4 minutes: comprise the whole sufficient pawl swelling of ankle joint), per 3 days records are once.The 6th day rat begins administration behind the Yu Zhiyan, wherein, and first and second group rat oral gavage distilled water 10ml/kg, the 3rd to five group of rat oral gavage granule 0.67,1.35 of the present invention and 2.70g/kg, the 6th group of rat oral gavage ZHENGQINGFENGTONGNING PIAN 2.70g/kg.1 time/day, continuous 7 days, inject administration 7 days in the same way again in the 19th day in adjuvant, experimental session is observed the body weight of rat, and the situation of inflammatory reaction is estimated drug effect
(1)
2, granule of the present invention is to the influence of rat acute gouty arthritis
Uric acid sodium (MSU) is made into 100mg/ml suspension with preceding with physiological saline solution in high temperature (200 ℃) sterilization.Get 60 of rats, ♀ ♂ half and half divides 6 groups at random by body weight. first group of rat oral gavage distilled water 10ml/kg, the 2nd group of rat oral gavage TONGFENGDING 2.70g/kg, 3-5 group rat is irritated stomach granule 0.67,1.35 of the present invention and 2.70g/kg, 1 time/day respectively, continuous 7 days, behind the last administration 1h, each is organized the right back sufficient subcutaneous injection 0.1ml uric acid sodium crystallization suspension of rat (100mg/ml) and causes inflammation, and mensuration causes before the inflammation and causes scorching back 0.5h, 1～6h rat foot volume is per hour measured an and is calculated the swelling degree
(2)
The scorching front foot volume of the scorching metapedes volume of swelling degree=cause-cause
3, granule of the present invention is to the influence of mice delayed hypersensitive reaction
Get 50 of mices, ♂ ♀ half and half divides 5 groups at random by body weight, is respectively the blank group, positive controls. three dosage groups of granule of the present invention, blank group mouse stomach distilled water 10ml/kg, positive controls mouse stomach hydrocortisone 20mg/kg.Three dosage groups of granule of the present invention are irritated stomach granule 1.0,2.0 of the present invention and 4.0g/kg respectively.Be administered once every day, successive administration 7 days.After the last administration second day, the mouse web portion depilation, and be coated with dinitrochlorobenzene (DNCB) ethanol liquid sensitization (5% in depilation place, 10 μ l/ are only). after the sensitization the 7th day, being coated with the inside and outside auricle of auris dextra with 5%DNCB ethanol liquid (20 μ l/ are only) attacks. attack back 24h, mice is put to death in dislocation, lays left and right sides ear same area auricle with the device that fans the air of diameter 6mm, and weighs. and calculate the swelling degree
(1)
Swelling degree=auris dextra auricle weight-left ear auricle is heavy
4, granule xylol of the present invention causes the influence of mice ear
Get 50 of mices, ♂ ♀ half and half divides 5 groups at random by body weight, is respectively the blank group, positive controls. three dosage groups of granule of the present invention, blank group mouse stomach distilled water 10ml/kg, positive controls mouse stomach indomethacin 15mg/kg.Three dosage groups of granule of the present invention mice is irritated stomach granule 1.0,2.0 of the present invention and 4.0g/kg respectively.Be administered once every day, successive administration 7 days.Behind last administration 1h, 30 μ l dimethylbenzene are applied to the mouse right ear two sides cause inflammation, cause the 45min dislocation of scorching back and put to death mice, lay left and right sides ear same area auricle with the device that fans the air of diameter 6mm, weigh. and calculate the swelling degree
(1)
Swelling degree=auris dextra auricle weight-left ear auricle is heavy
5, granule of the present invention causes the influence of pain to the mice chemical stimulation
50 of mices, ♀ ♂ half and half divides 5 groups at random, and first group is the blank group, irritates stomach distilled water 10ml/kg, second group of positive matched group, the oral indomethacin 15mg/kg of mice.The three-five group of mice irritated stomach granule 1.0,2.0 of the present invention and 4.0g/kg g/kg respectively.After each organized mice administration 1h, lumbar injection 0.6% acetum 0.2ml/ only respectively.Each Mus is turned round the body number of times in the observed and recorded 15min, carries out statistical procedures
(3)
6, the preparation of freund adjuvant:
After the anhydrous lanolin heating and melting, cooling is got 5ml in mortar slightly, the dropping liquid paraffin body 10ml dropwise while grinding, and 70 ℃ of water-baths are heat altogether, abundant mixing, autoclaving (8 pounds, 60 minutes).The above-mentioned anhydrous lanolin and the liquid paraffin mixed liquor 6ml that get after the sterilization place mortar, get bacillus calmette-guerin vaccine 60mg/ bottle, use a small amount of physiological saline solution, drip bacillus calmette-guerin vaccine while grinding in mortar, fully grind mixing and get the complete freund adjuvant that concentration is 10mg/ml
(2)
Experimental result:
1, granule of the present invention is to the influence of rat assist agent arthritis
Inject complete freund adjuvant and can cause the direct inflammatory reaction of rat injection site, thereafter also can produce the inflammatory reaction of a series of secondary, comprise the swelling of non-injection acra, the reactions such as arthritis tuberosity that afterbody, ear occur, this series reaction of observed and recorded can be used for evaluate efficacy.
Attack the direct inflammatory reaction that causes the rat injection site for complete freund adjuvant: normal rat is more stable at experimental session foot volume, the just growth of follower body weight, and some becomes big sufficient volume.The rat foot begins swelling after injecting complete freund adjuvant, and with the prolongation of moulding time, the aggravation of the degree of swelling.After granule of the present invention was given rat oral gavage, the swelling that adjuvant is caused had certain inhibitory action.And strengthen with the dosage of medicine, (table 1) strengthened in the effect of adjuvant-induced arthritis.
Table 1 granule of the present invention is to the influence of adjuvant-induced arthritis
| Group | Dosage (g/kg) | Before the moulding | 3h after the moulding | 18h | 3d | 6d (sufficient volume ml) |
| Normal control group arthritis matched group granule of the present invention granule of the present invention granule ZHENGQINGFENGTONGNING PIAN of the present invention | - - 0.67 1.35 2.70 2.70 | 1.46±0.11 1.40±0.08 1.40±0.07 1.39±0.11 1.49±0.11 1.48±0.08 | 1.44±0.09 1.97±0.21 1.80±0.18 1.97±0.14 1.77±0.19 1.83±0.13 | 1.44±0.10 2.33±0.20 # 2.02±0.25 2.40±0.26 2.17±0.20 2.04±0.33 | 1.51±0.08 2.47±0.27 # 2.34±0.32 2.45±0.33 2.17±0.36 2.19±0.28 | 1.55±0.08 2.70±0.37 # 2.20±0.19 * 2.44±0.28 1.94±0.31 * 2.01±0.17 * |
| Group | Dosage (g/kg) | 9d after the moulding | 12d | 15d | 18d | 21d (sufficient volume ml) |
| Normal control group arthritis matched group granule of the present invention granule of the present invention granule ZHENGQINGFENGTONGNING PIAN of the present invention | - - 0.67 1.35 2.70 2.70 | 1.60±0.06 2.61±0.34 # 2.24±0.29 2.35±0.31 2.09±0.21 * 1.99±0.13 * | 1.62±0.06 2.64±0.56 # 2.37±0.38 2.49±0.45 2.33±0.17 1.92±0.15 * | 1.69±0.07 2.83±0.53 # 2.32±0.41 2.69±0.41 2.28±0.31 * 1.95±0.22 ** | 1.71±0.07 3.05±0.47 # 2.46±0.31 * 2.58±0.29 * 2.22±0.27 ** 2.04±0.21 ** | 1.73±0.13 2.85±0.47 # 2.47±0.30 2.30±0.34 * 2.11±0.22 ** 1.98±0.26 ** |
N=10, with the normal control group than #p＜0.01.With arthritis matched group ratio
*P＜0.05,
*P＜0.01.
Complete freund adjuvant is attacked the preventive effect that causes the inflammatory reaction of rat secondary: inject administration in the 6th to the 13 day in adjuvant, and during the administration and detect the secondary inflammatory reaction of rat after the administration, by table 2 data as can be seen: normal rat secondary reactions do not occur at experimental session.After injecting complete freund adjuvant, rat shows left foot swelling, left and right pawl swelling, tuberosity appears in afterbody, ear, injects in adjuvant and can see some secondary reactions signs on the tenth day, to adjuvant injection 13 days, it is fairly obvious that secondary reactions becomes, wherein the secondary reactions of model control group performance is more obvious, and granule of the present invention causes that to adjuvant the generation of secondary reactions has inhibitory action (table 2) after giving rat oral gavage.Point out granule of the present invention inhibited to the generation of arthritis model.
Table 2 granule of the present invention is to the influence of adjuvant arthritis rats secondary reactions
| Group | Dosage (g/kg) | 10d after the moulding | 13d | 16d (mark) |
| Normal control group model matched group granule of the present invention granule of the present invention granule of the present invention | - - 0.67 1.35 2.70 | 0 2.8±1.3 1.0±0.7 * 0.9±0.7 * 0.5±0.5 ** | 0 4.6±1.1 1.9±1.0 * 1.7±0.7 * 0.7±0.7 ** | 0 4.7±1.4 2.7±1.3 * 2.5±1.0 * 1.1±0.7 ** |
| ZHENGQINGFENGTONGNING PIAN | 2.70 | 1.4±0.7 * | 2.0±1.2 * | 2.6±1.1 * |
| Group | Dosage (g/kg) | 19d after the moulding | 22d | 25d (mark) |
| Normal control group model matched group granule of the present invention granule of the present invention granule ZHENGQINGFENGTONGNING PIAN of the present invention | - - 0.67 1.35 2.70 2.70 | 0 5.7±0.7 3.6±1.5 * 3.2±0.8 ** 1.3±1.3 ** 2.9±0.9 ** | 0 5.2±1.4 4.1±1.4 2.8±0.9 ** 0.3±0.5 ** 2.9±1.0 ** | 0 6.4±1.1 4.4±1.4 * 2.2±0.8 ** 0.3±0.7 ** 2.6±1.2 ** |
N=10 is with the model control group ratio
*P＜0.05.
**p＜0.01。
2, granule of the present invention is to the influence of rat acute gouty arthritis
Uric acid sodium can be simulated the gouty arthritis model, and after uric acid sodium was expelled to rat foot pad, the rat foot began swelling, only irritate the rat of stomach distilled water, the degree of foot swelling is bigger, irritates the middle and high dosage of stomach granule of the present invention in advance, and the swelling that uric acid sodium is caused has certain inhibitory action (table 3).
Table 3 granule of the present invention is to the influence of rat acute gouty arthritis
| Group | Dosage (g/kg) | 0.5h after the moulding | 1h | 2h | 3h (swelling degree ml) |
| Model control group TONGFENGDING group granule of the present invention granule of the present invention granule of the present invention | - 2.70 0.67 1.35 2.70 | 0.43±0.17 0.12±0.17 ** 0.23±0.29 0.20±0.23 * 0.11±0.28 ** | 0.46±0.17 0.09±0.17 ** 0.23±0.26 0.19±0.22 * -0.03±0.24 ** | 0.62±0.18 0.30±0.13 * 0.27±0.36 * 0.16±0.25 ** 0.14±0.37 ** | 0.56±0.23 0.05±0.31 ** 0.31±0.36 0.19±0.30 ** 0.26±0.45 ** |
| Group | Dosage (g/kg) | 4h after the moulding | 5h | 6h (swelling degree ml) |
| Model control group | - | 0.52±0.20 | 0.63±0.27 | 0.63±0.18 |
| TONGFENGDING group granule of the present invention granule of the present invention granule of the present invention | 2.70 0.67 1.35 2.70 | 0.26±0.23 * 0.34±0.33 0.19±0.27 ** 0.22±0.40 * | 0.39±0.22 0.59±0.47 0.33±0.36 * 0.50±0.40 * | 0.43±0.28 0.37±0.47 0.35±0.27 0.42±0.38 |
N=10 is with the model control group ratio
*P＜0.05.
**p＜0.01。
3, granule of the present invention is to the influence to the mice delayed hypersensitive reaction
The formation of rheumatic arthritis and antigen antibody complex are in the deposition of collagen tissue, and then the reaction that causes inflammation is relevant.Ideal antarthritic should suppress tissue injury, the reaction that reduces inflammation, and therefore experiment adopts dinitrochlorobenzene as immunologic stimulant, estimates the influence of granule of the present invention to delayed hypersensitive reaction.Dinitrochlorobenzene makes animal produce allergy as a kind of immunologic stimulant.Normal mouse ear accepts dinitrochlorobenzene smear after, the auricle of mice is swollen with, under fire the weight difference of ear and the identical auricle of irriate ear not is very remarkable in control group mice.Granule of the present invention significantly reduces the weight difference of the auricle of mice, illustrates that granule of the present invention has certain inhibitory action to delayed hypersensitive reaction, can alleviate the inflammatory reaction degree (table 4) of irriate ear.
Table 4 granule of the present invention is to the influence of mice delayed hypersensitive reaction
| Group | Dosage (g/kg) | Swelling degree (mg) |
| Matched group hydrocortisone granule of the present invention granule of the present invention granule of the present invention | - 0.02 1.0 2.0 4.0 | 1.97±0.32 0.91±0.21 * 1.85±0.33 1.32±0.31 * 0.80±0.32 ** |
N=10 is with the matched group ratio
*P＜0.05.
**p＜0.01。
4, granule xylol of the present invention causes the influence of mice ear
After normal mouse was accepted dimethylbenzene and smeared, tangible inflammatory reaction appearred in the remarkable swelling in contact site.Granule xylol of the present invention causes mice ear inhibitory action, and presents certain dose-response relationship (table 5).
Table 5 granule of the present invention is to the influence of mice caused by dimethylbenzene xylene ear swelling
| Group | Dosage (g/kg) | Number of animals | Swelling degree (mg) |
| Matched group indomethacin granule of the present invention granule of the present invention granule of the present invention | - 0.015 1.0 2.0 4.0 | 10 10 10 10 10 | 1.17±0.18 0.62±0.21 ** 0.93±0.29 0.67±0.28 ** 0.70±0.28 ** |
With the matched group ratio
*P＜0.05,
*P＜0.01.
5, granule of the present invention causes the influence of pain to the mice chemical stimulation
The acetic acid lumbar injection makes animal produce pain as a kind of chemical stimulation, and this model class is similar to Encelialgia or arthralgic situation.After normal mouse was accepted acetic acid injection, painful as repeatedly to turn round body, that significantly reduces mice after the administration of positive drug indomethacin turned round the body number of times.Granule of the present invention also makes the body number of times of turning round of mice significantly reduce, and relatively there were significant differences with matched group, and be certain dose-response relationship (table 6).
Table 6 granule of the present invention is to the influence of mouse writhing
| Group | Dosage (g/kg) | Number of animals | Turn round body number of times (inferior) |
| Normal control group indomethacin granule of the present invention granule of the present invention granule of the present invention | - 0.015 1.0 2.0 4.0 | 10 10 10 10 10 | 35.2±6.0 15.7±3.4 ** 23.2±5.3 ** 18.7±3.5 ** 13.8±4.5 ** |
With normal control group ratio
*P＜0.01.
Brief summary:
By the adjuvant arthritis animal model, chemical inflammatory model, chemical substance cause the effects of animal model investigation granule of the present invention aspect antiinflammatory, analgesia and treatment rheumatic, rheumatoid, gouty arthritis such as pain.The result shows that granule of the present invention has significant inhibitory effect to adjuvant-induced arthritis and gouty arthritis.Can reduce the mouse writhing number of times that acetic acid causes, xylol causes the mice inflammatory reaction remarkable inhibitory action, and the delayed hypersensitive reaction that dinitrochlorobenzene is brought out has certain inhibitory action.Point out granule of the present invention to have tangible antiinflammatory and analgesic activity.
Claims (6)
1, a kind of Chinese medicine composition for the treatment of rheumatic or rheumatoid arthritis or gout, it is made up of effective ingredient and/or acceptable accessories, and wherein its contained effective ingredient is made by the following weight proportion raw material: Rhizoma Atractylodis 5-15 part, raw pearl barley 10-30 part, Pheretima 5-15 part, Radix Stephaniae Tetrandrae 7-22 part, Cortex Phellodendri 5-15 part, Rhizoma Dioscoreae Hypoglaucae 7-22 part, Caulis Lonicerae 10-30 part, Radix Saposhnikoviae 5-15 part, Fructus Forsythiae 7-22 part, Radix Clematidis 6-18 part, Radix Cyathulae 7-22 part, Ramulus Mori 10-30 part.
2, according to the described Chinese medicine composition of claim 1, wherein said effective ingredient is made by the following weight proportion raw material: Rhizoma Atractylodis 7-13 part, raw pearl barley 15-25 part, Pheretima 7-13 part, Radix Stephaniae Tetrandrae 10-18 part, Cortex Phellodendri 7-13 part, Rhizoma Dioscoreae Hypoglaucae 10-18 part, Caulis Lonicerae 15-25 part, Radix Saposhnikoviae 7-13 part, Fructus Forsythiae 10-18 part, Radix Clematidis 9-15 part, Radix Cyathulae 10-18 part, Ramulus Mori 15-25 part.
3, according to the described Chinese medicine composition of claim 1, it is tablet, capsule or granule.
4, according to the preparation method of claim 1 or 2 described Chinese medicine compositions, it comprises decocting after the described raw material of Chinese medicine coarse pulverization or the direct decocting of the prepared slices of Chinese crude drugs, filter, obtain the water extract of above-mentioned raw materials, again with itself and/or and mixing acceptable accessories.
5, according to the preparation method of claim 1 or 2 described Chinese medicine compositions, it comprises pulverizes Fructus Forsythiae, Semen Coicis, Radix Stephaniae Tetrandrae, crosses the 100-200 mesh sieve, all the other 9 flavor medicines are decocting together, filter, filtrate is concentrated into the clear paste of relative density 1.1-1.4 (50 ℃), with clear paste and above-mentioned medicinal powder mixing; Again with itself and/or and mixing acceptable accessories.
6, according to the preparation method of claim 1 or 2 described Chinese medicine compositions, it comprises extracts volatile oil with Rhizoma Atractylodis, Fructus Forsythiae, Radix Saposhnikoviae; All the other 9 flavors with decoction and alcohol sedimentation technique extract, purification, the back concentrates the clear paste that makes relative density 1.1-1.4 (50 ℃), with itself and/or and mixing acceptable accessories, drying adds volatile oil.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100119613A CN100488552C (en) | 2005-06-17 | 2005-06-17 | Chinese medicine composition for treating arthritis or gout and preparing method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNB2005100119613A CN100488552C (en) | 2005-06-17 | 2005-06-17 | Chinese medicine composition for treating arthritis or gout and preparing method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1836720A true CN1836720A (en) | 2006-09-27 |
| CN100488552C CN100488552C (en) | 2009-05-20 |
Family
ID=37014314
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB2005100119613A Active CN100488552C (en) | 2005-06-17 | 2005-06-17 | Chinese medicine composition for treating arthritis or gout and preparing method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN100488552C (en) |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391521C (en) * | 2005-10-25 | 2008-06-04 | 辽宁本溪三药有限公司 | Chinese medicine for treating damp heat arthralgia and its preparation method |
| CN100444871C (en) * | 2007-01-09 | 2008-12-24 | 河南太龙药业股份有限公司 | Atoxic traditional Chinese medicine composition for treating rheumatosis and rheumatoid disease |
| CN101850063A (en) * | 2010-04-02 | 2010-10-06 | 贵阳春科药业技术研发有限公司 | Medicinal preparation for preventing and treating gout and preparation method |
| CN101670058B (en) * | 2009-09-25 | 2011-06-22 | 孙红梅 | Traditional Chinese medicine composition for treating gout |
| CN101843724B (en) * | 2009-10-22 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating gout |
| CN101380414B (en) * | 2007-09-06 | 2012-01-25 | 中山大学附属第一医院 | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof |
| CN102406868A (en) * | 2011-11-08 | 2012-04-11 | 文登市口腔医院米山路口腔诊所 | Chinese medicine for treating rheumarthritis |
| CN103100003A (en) * | 2013-02-21 | 2013-05-15 | 杨志彩 | Traditional Chinese medicine composition for treating acute gouty arthritis |
| CN103127428A (en) * | 2013-03-27 | 2013-06-05 | 谢银芳 | Chinese patent drug for treatment of gouty arthritis |
| CN103386033A (en) * | 2013-06-27 | 2013-11-13 | 张兴保 | Deer blood wine for treating rheumatism and gout and preparation method thereof |
| CN103417873A (en) * | 2013-08-21 | 2013-12-04 | 宋立学 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
| CN103908527A (en) * | 2014-04-06 | 2014-07-09 | 杨有贵 | Traditional Chinese medicine for treating rheumatism |
| CN103920024A (en) * | 2014-05-04 | 2014-07-16 | 李万水 | Medicinal preparation for treating gout and preparation method thereof |
| CN105362696A (en) * | 2015-12-15 | 2016-03-02 | 钟柏根 | Medicine composition for treating gouty arthritis and application thereof |
| CN105833117A (en) * | 2016-05-17 | 2016-08-10 | 刘喜德 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
| CN107261013A (en) * | 2017-05-28 | 2017-10-20 | 成都风靡生物科技有限公司 | The capsule medicine and preparation method of a kind for the treatment of of arthritis and gout |
-
2005
- 2005-06-17 CN CNB2005100119613A patent/CN100488552C/en active Active
Cited By (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100391521C (en) * | 2005-10-25 | 2008-06-04 | 辽宁本溪三药有限公司 | Chinese medicine for treating damp heat arthralgia and its preparation method |
| CN100444871C (en) * | 2007-01-09 | 2008-12-24 | 河南太龙药业股份有限公司 | Atoxic traditional Chinese medicine composition for treating rheumatosis and rheumatoid disease |
| CN101380414B (en) * | 2007-09-06 | 2012-01-25 | 中山大学附属第一医院 | Traditional Chinese medicine composition for treating gout and hyperuricemia and preparation method thereof |
| CN101670058B (en) * | 2009-09-25 | 2011-06-22 | 孙红梅 | Traditional Chinese medicine composition for treating gout |
| CN101843724B (en) * | 2009-10-22 | 2011-11-23 | 北京绿源求证科技发展有限责任公司 | Chinese medicament for treating gout |
| CN101850063A (en) * | 2010-04-02 | 2010-10-06 | 贵阳春科药业技术研发有限公司 | Medicinal preparation for preventing and treating gout and preparation method |
| CN102406868A (en) * | 2011-11-08 | 2012-04-11 | 文登市口腔医院米山路口腔诊所 | Chinese medicine for treating rheumarthritis |
| CN102406868B (en) * | 2011-11-08 | 2013-08-07 | 刘运波 | Chinese medicine for treating rheumarthritis |
| CN103100003B (en) * | 2013-02-21 | 2014-07-23 | 徐鹏 | Traditional Chinese medicine composition for treating acute gouty arthritis |
| CN103100003A (en) * | 2013-02-21 | 2013-05-15 | 杨志彩 | Traditional Chinese medicine composition for treating acute gouty arthritis |
| CN103127428A (en) * | 2013-03-27 | 2013-06-05 | 谢银芳 | Chinese patent drug for treatment of gouty arthritis |
| CN103386033A (en) * | 2013-06-27 | 2013-11-13 | 张兴保 | Deer blood wine for treating rheumatism and gout and preparation method thereof |
| CN103386033B (en) * | 2013-06-27 | 2016-01-20 | 张兴保 | A kind of deer-blood wine and preparation method thereof for the treatment of rheumatism, gout |
| CN103417873A (en) * | 2013-08-21 | 2013-12-04 | 宋立学 | Traditional Chinese medicine composition for treating gout and preparation method thereof |
| CN103417873B (en) * | 2013-08-21 | 2016-02-24 | 宋立学 | The Chinese medicine composition for the treatment of gout and preparation method |
| CN103908527A (en) * | 2014-04-06 | 2014-07-09 | 杨有贵 | Traditional Chinese medicine for treating rheumatism |
| CN103920024A (en) * | 2014-05-04 | 2014-07-16 | 李万水 | Medicinal preparation for treating gout and preparation method thereof |
| CN105362696A (en) * | 2015-12-15 | 2016-03-02 | 钟柏根 | Medicine composition for treating gouty arthritis and application thereof |
| CN105833117A (en) * | 2016-05-17 | 2016-08-10 | 刘喜德 | Traditional Chinese medicine composition for treating rheumatoid arthritis |
| CN107261013A (en) * | 2017-05-28 | 2017-10-20 | 成都风靡生物科技有限公司 | The capsule medicine and preparation method of a kind for the treatment of of arthritis and gout |
Also Published As
| Publication number | Publication date |
|---|---|
| CN100488552C (en) | 2009-05-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN100488552C (en) | Chinese medicine composition for treating arthritis or gout and preparing method thereof | |
| CN1861163A (en) | Traditional Chinese medicine composition for treating kidney-yang deficiency and deficiency of vital energy and blood, its prepn. process | |
| CN102058673B (en) | Chinese medicine composition for expelling wind and removing dampness and preparation method thereof | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN104491052B (en) | Traditional Chinese medicine composition for treating rheumatic and rheumatoid arthritis and preparation method thereof | |
| CN1712054A (en) | Qinchuan Tongbi tablet | |
| CN101167937A (en) | Traditional Chinese medicinal composition plaster for curing rheumatism or rheumatoid diseases and preparation method thereof | |
| CN111481638A (en) | Traditional Chinese medicine enema preparation for treating ulcerative colitis and preparation method thereof | |
| CN1311010A (en) | Smoke inhaling article for medical use, and its mfg. method | |
| CN1836693A (en) | Chinese medicine composition for treating arthritis and preparing method thereof | |
| CN101032604A (en) | Chinese medicine preparation for curing vascular type headache | |
| CN1840160A (en) | Powder for resisting hyperosteogeny | |
| CN1256120C (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN100363043C (en) | Chinese traditional medicine composition for treating rheumatic or rheumatoid disease and preparation method thereof | |
| CN1634479A (en) | Medicine composition for treating cold and upper respiratory tract infection, preparation method and purpose thereof | |
| CN1168488C (en) | Chinese medicinal preparation for treating pyretic stranguria | |
| CN100335044C (en) | Rhinitis treating soft medicinal capsule and preparation process thereof | |
| CN1686424A (en) | Medicinal composition containing scutellaria and bupleurum and its preparation method | |
| CN1148217C (en) | Chinese medicine for treating chronic bronchitis | |
| CN1130212C (en) | Medicine for treating abdominal node and its preparing process | |
| CN1973850A (en) | Medicine composition for treating allergic rhinitis and its prepn process | |
| CN1248709C (en) | Chinese medicine prepn for stopping drug addiction | |
| CN101028451A (en) | Chinese medicine for treating tic douloureux | |
| CN101032540A (en) | Medicine composition for curing arthritis and the preparing method and purpose thereof | |
| CN1251751C (en) | Chinese traditional medicine for treating chronic liver disease and anti hepatic fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| ASS | Succession or assignment of patent right |
Owner name: LIAONING HAOHUSHI MEDICINE ( GROUP ) CO., LTD. Free format text: FORMER OWNER: BENXI TIANYIN PHARMACEUTICAL CO., LTD. Effective date: 20070803 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20070803 Address after: 117201 Xin'an street, Heng Jen Town, Liaoning constant Manchu Manchu Autonomous County Applicant after: Haohushi Pharmaceutical (Group) Co., Ltd., Liaoning Address before: 117004 Benxi Liaoning economic and Technological Development Zone Medical Park Applicant before: Benxi Tianyin Pharmaceutical Co., Ltd. |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee | ||
| CP03 | Change of name, title or address |
Address after: 117201, No. 6, Taishan Road, five female mountain Economic Development Zone, Huanren County, Liaoning, Benxi Patentee after: Liaoning medicine good nurse (Group) Co. Ltd. Address before: 117201 Xin'an street, Heng Jen Town, Liaoning constant Manchu Manchu Autonomous County Patentee before: Liaoning Haohushi Pharmaceutical Co., Ltd. |